ZYME Stock Overview
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zymeworks Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.66 |
| 52 Week High | US$13.14 |
| 52 Week Low | US$6.02 |
| Beta | 1.11 |
| 1 Month Change | -17.76% |
| 3 Month Change | -12.35% |
| 1 Year Change | -11.90% |
| 3 Year Change | -68.80% |
| 5 Year Change | -48.94% |
| Change since IPO | -33.38% |
Recent News & Updates
Recent updates
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 27
We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth
Nov 17Zymeworks: Drop Due To Low Differentiation Against Competition
Jul 05Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals
Dec 11Zymeworks' zanidatamab nabs Breakthrough Therapy tag for biliary tract cancer
Nov 30Zymeworks' zanidatamab an Orphan Drug in Europe for gastric cancer
Nov 19Shareholder Returns
| ZYME | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.5% | -4.2% | -3.7% |
| 1Y | -11.9% | -2.0% | 20.5% |
Return vs Industry: ZYME underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: ZYME underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ZYME volatility | |
|---|---|
| ZYME Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZYME's share price has been volatile over the past 3 months.
Volatility Over Time: ZYME's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 275 | Ken Galbraith | www.zymeworks.com |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. Fundamentals Summary
| ZYME fundamental statistics | |
|---|---|
| Market cap | US$611.12m |
| Earnings (TTM) | -US$118.67m |
| Revenue (TTM) | US$76.01m |
8.0x
P/S Ratio-5.1x
P/E RatioIs ZYME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYME income statement (TTM) | |
|---|---|
| Revenue | US$76.01m |
| Cost of Revenue | US$142.99m |
| Gross Profit | -US$66.98m |
| Other Expenses | US$51.70m |
| Earnings | -US$118.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -1.68 |
| Gross Margin | -88.11% |
| Net Profit Margin | -156.13% |
| Debt/Equity Ratio | 0% |
How did ZYME perform over the long term?
See historical performance and comparison